Drug development firm SkyePharma said expectations for 2012 pre-exceptional operating profit remain unchanged and is confident of future trading as it launches its asthma treatment product flutiform across Europe.
[15 Oct '12]Infrastructure India, an AIM-listed investment group, pleased its investors with a 50.2 per cent leap in its net asset value (NAV) to 207.3m pounds over the year ended March. The value of the company's investments rose 94.9 per cent to 216.7m pounds, while the NAV per share climbed from 92p to 95p. The company's Chairman said the period was one of "significant operating progress" in what has been a challenging period for investing in Indian infrastructure and stressed that it
[23 Aug '12]Also contained in this round-up: Coral Products SkyePharma, SimiGon, Tri-Star Resources and PHSC.
[17 Jul '12]SkyePharma said the European Commission had given it the go-ahead to start marketing its asthma medicine, flutiform, across the continent.
[3 Jul '12]The resources investment firm Creon Resources is to raise 12.1m pounds from an open offer, with around 2.4bn shares up for sale at 0.5p per share, a 1.5p discount to the share price at the close yesterday. Jeswant Natarajan, Chief Executive Officer of Creon, commented: 'Today's announcement...is extremely positive news for Creon given its difficult historic trading performance since its inception, and provides the directors with a number of possibilities in executing its inve
[22 Jun '12]Miniature table-top war games firm Games Workshop said trading in the four months to the beginning of April has been broadly in line with the board's expectations.
[20 Apr '12]Also included in this round-up: Angle, Music Festivals, Manroy
[11 Apr '12]Shares in SkyePharma rose despite the drug development firm reporting a fall in revenue and a plunge into the red for the year ended December 31st.
[22 Mar '12]